CHARGED ALPHATMFrontier AI stock research

WST · NYSE

West Pharmaceutical Services Inc.

Medical Instruments & Supplies · United States

USD 375.51-0.3% daily changeQuote 2026-10-06 · USD
Market cap (USD)
US$26.43B
Trailing P/E
48.08x
Forward P/E
37.63x
Quarterly revenue growth
13.8%
Trailing net margin
17.0%
Indicated dividend yield
0.2%

Snapshot 2026-10-06 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.

Next earnings: 2026-10-22 (provider estimate, not issuer-confirmed).

Company background

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Company website

Q2 2026

Go beyond the headline.

West Pharmaceutical Stock: It Beat & RAISED on the GLP-1 Boom — Is WST a Buy Now?

Published 2026-07-23

Comparable businesses

WST peer comparison

Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.

Comparison stocks

Market metrics · missing or inapplicable values shown as —
MetricWSTWest Pharmaceutical Services, Inc.Snapshot 2026-10-06Financial period: 2026-06-30RMDResMed Inc.Snapshot 2026-10-06Financial period: 2026-06-30ALCAlcon Inc.Snapshot 2026-10-06Financial period: 2026-06-30Peer medianSimilar-size peers only
Market capMarket value, converted to USDUS$26.43BUS$31.45BUS$30.66BUS$31.06Bn=2
Forward P/EProvider forward earnings estimate37.63x16.90x15.98x16.44xn=2
EV / EBITDAEnterprise value / trailing EBITDA28.94x15.03x14.53x14.78xn=2
Revenue growthLatest quarter vs prior-year quarter13.8%8.6%8.7%8.6%n=2
Operating marginLatest reported quarter22.5%30.9%14.6%22.7%n=2
Free cash flow yieldTrailing cash flow / market cap1.1%3.0%4.2%3.6%n=2
Net debt / EBITDANet debt / trailing EBITDA-0.13x-0.31x1.60x0.65xn=2
Debt / equityTotal debt / positive book equity0.11x0.13x0.25x0.19xn=2
Trailing P/ETrailing twelve-month earnings48.08x21.44x48.05x34.74xn=2
Price / bookPrice / positive book equity per share8.84x4.90x1.42x3.16xn=2
EV / salesEnterprise value / trailing revenue7.93x5.57x3.22x4.40xn=2
Earnings growthLatest quarter vs prior-year quarter18.1%2.4%——
Gross marginTrailing twelve months36.8%61.6%57.2%59.4%n=2
Net marginTrailing twelve months17.0%26.9%5.9%16.4%n=2
Return on equityProvider trailing return; positive equity only19.1%24.3%2.9%13.6%n=2
Free cash flow marginTrailing free cash flow / revenue8.4%16.6%11.7%14.2%n=2
Dividend yieldIndicated annual dividend / price0.2%1.2%0.6%0.9%n=2
Earnings payoutProvider trailing dividend payout11.1%23.0%26.6%24.8%n=2
Current ratioCurrent assets / current liabilities2.82x3.10x2.09x2.60xn=2
BetaProvider historical market sensitivity1.120.750.730.74n=2

Choose a comparison stock

Search covered companies, or search all listed stocks.

Comparison methodology & limitations

Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.

Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.

Reported performance

Financial trends

Reporting period
Financial history
Chart style
Comparison stocks

Financial statements load separately from the research page.

Market context

Valuation & price history

Adjusted closing price

Price history

Price history loads separately.

Earnings-multiple scenario

Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.

Starting assumptions, when available, use provider forward estimates as of 2026-10-06. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.

THE RESEARCH RECORD

Research history for WST

All available reporting periods
Q2 20262026-07-23
Q1 20262026-04-26
Deep Dive2026-04-25

Reported figures

Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.